JS108 / Shanghai Junshi Biosci, Hangzhou DAC Biotech - LARVOL DELTA

A Phase I Study of JS108 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=25 | Terminated | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=153 ➔ 25 | Trial completion date: Nov 2023 ➔ Jun 2023 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2023 ➔ Jun 2023; Sponsor has adjusted study development plan and terminated this clinical study.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

A Phase I Study of JS108 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=153 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Trial completion date: Nov 2022 ➔ Nov 2023 | Trial primary completion date: Nov 2022 ➔ Oct 2023

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase I Study of JS108 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=153; Recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate (GlobeNewswire) - "...JS108 clinical trial application was approved by the National Medical Products Administration (NMPA)....Junshi has entered an exclusive license agreement with Hangzhou DAC Biotech Co., Ltd. ('Hangzhou DAC'), to develop and commercialize JS108 (anti-TROP2-ADC) in Asian countries and regions excluding Japan and South Korea."

Licensing / partnership • Non-US regulatory • Breast Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

Junshi Bio doses first patient with Trop2-Tub196 ADC in China Phase I (GBI Health) - "Shanghai-based biotech Junshi Biosciences (HKEX:1877; SSE:688180) announced the first patient dosing in a Phase I clinical study for JS108, a Trop2 monoclonal antibody (mAb)-Tub196 antibody drug conjugate (ADC) candidate. JS108 is under co-development with DAC Bio to treat Trop2-positive triple-negative breast cancer, small cell lung cancer (SCLC), pancreatic cancer, and other solid tumors."

Trial status • Breast Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

A Phase I Study of JS108 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=153; Not yet recruiting; Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor